A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

Solid Neoplasms Clinical Trial

Official title:
An Open-Label Phase 1b/2 Study of E7389 Liposomal Formulation Plus Nivolumab in Subjects With Solid Tumor

Status Active, not recruiting

Clinical Trial Summary

The primary purpose of the study is to evaluate safety and tolerability and to determine recommended Phase 2 dose (RP2D) of E7389-LF in combination with nivolumab in Phase 1b part, and to evaluate objective response rate (ORR) of E7389-LF and nivolumab using RP2D in Phase 2 part in each tumor type.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04078295
Study type	Interventional
Source	Eisai Inc.
Contact
Status	Active, not recruiting
Phase	Phase 1/Phase 2
Start date	September 5, 2019
Completion date	January 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT02896049` - Celsius TCS Hyperthermia System PMCF Trial
Active, not recruiting	`NCT03833700` - A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)	Phase 1
Recruiting	`NCT04407676` - Improving Informed Consent for Early Phase Anti-Cancer Trials	N/A
Recruiting	`NCT04420884` - A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors	Phase 1/Phase 2
Completed	`NCT03364049` - Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002)	Phase 1
Completed	`NCT01543282` - Endoscopic Ultrasonography (EUS) Guided Fine Needle Aspiration Using Free Stylet 22g and 25 g Needles	N/A